Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma?

Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence... CLINICAL TRIALS Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results Jithin Yohannan, BA; Beatriz Munoz, MS; Harran Mkocha, BS; Charlotte A. Gaydos, PhD; Robin Bailey, MD, PhD; Thomas A. Lietman, MD; Thomas Quinn, MD; Sheila K. West, PhD Importance: The World Health Organization recom- Interventions: Cessation of MDA with azithromycin mends at least 3 annual mass drug administrations if the community had no infection in their sample at 6 (MDAs) of azithromycin in places where the prevalence months or 18 months. of follicular trachoma (FT) is greater than 10%. How- ever, stopping MDA prior to 3 rounds, if monitoring in- Main Outcome Measure: The prevalence of C tra- dicates an absence of infection with Chlamydia tracho- chomatis at 18 months. matis even if FT persists, may be more cost-effective. Results: None of the intervention communities met cri- Objective: To determine the prevalence of infection in teria to stop MDA based on the 6-month or 18-month communities randomized to 3 rounds of annual MDAs survey; all, as well as the usual care communities, were with azithromycin compared with communities random- scheduled for a third MDA round. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma?

Loading next page...
 
/lp/american-medical-association/can-we-stop-mass-drug-administration-prior-to-3-annual-rounds-in-jHL80KPkdZ
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2013.2356
pmid
23392481
Publisher site
See Article on Publisher Site

Abstract

CLINICAL TRIALS Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results Jithin Yohannan, BA; Beatriz Munoz, MS; Harran Mkocha, BS; Charlotte A. Gaydos, PhD; Robin Bailey, MD, PhD; Thomas A. Lietman, MD; Thomas Quinn, MD; Sheila K. West, PhD Importance: The World Health Organization recom- Interventions: Cessation of MDA with azithromycin mends at least 3 annual mass drug administrations if the community had no infection in their sample at 6 (MDAs) of azithromycin in places where the prevalence months or 18 months. of follicular trachoma (FT) is greater than 10%. How- ever, stopping MDA prior to 3 rounds, if monitoring in- Main Outcome Measure: The prevalence of C tra- dicates an absence of infection with Chlamydia tracho- chomatis at 18 months. matis even if FT persists, may be more cost-effective. Results: None of the intervention communities met cri- Objective: To determine the prevalence of infection in teria to stop MDA based on the 6-month or 18-month communities randomized to 3 rounds of annual MDAs survey; all, as well as the usual care communities, were with azithromycin compared with communities random- scheduled for a third MDA round.

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 1, 2013

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month